"Are you looking for a long term weight loss plan tailor to your needs and at an affordable plan?"
Each of our weight-management programs begins with an initial consultation and includes a medically supervised B12 fat-burn injection to enhance energy and support metabolism.
SEMAGLUTIDE (GLP-1)
Wegovy (semaglutide) is an FDA-approved prescription medication used for chronic weight management in adults with obesity or overweight who also have weight-related health conditions. It belongs to a class of drugs called GLP-1 receptor agonists, which work by mimicking a natural hormone that regulates appetite and food intake. By slowing gastric emptying and helping control cravings, Wegovy supports reduced calorie intake and promotes significant, sustained weight loss when combined with a healthy diet and regular physical activity.
Ozempic (semaglutide) is an FDA-approved prescription medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to the class of GLP-1 receptor agonists, which mimic a natural hormone that helps regulate blood sugar by stimulating insulin release, reducing glucagon levels, and slowing digestion. In addition to managing diabetes, Ozempic has also been shown to support weight loss and reduce the risk of major cardiovascular events in people with type 2 diabetes and established heart disease.
LIRATITUDE (GLP-1)
Saxenda (liraglutide) is an FDA-approved prescription medication for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition, such as high blood pressure or type 2 diabetes. As a GLP-1 receptor agonist, it helps regulate appetite by slowing digestion and promoting a feeling of fullness, which supports reduced calorie intake and weight loss. Saxenda is administered as a once-daily injection and is most effective when combined with a healthy diet and excercise.
Victoza (liraglutide) is an FDA-approved prescription medication used to improve blood sugar control in adults and children 10 years and older with type 2 diabetes. It belongs to the class of GLP-1 receptor agonists, which work by stimulating insulin release, reducing glucagon levels, and slowing digestion to help regulate blood glucose. In addition to its diabetes benefits, Victoza has been shown to lower the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. It is administered as a once-daily injection and is most effective when combined with healthy diet and exercise.
TIRZEPATIDE (GLP-1/GIP)
Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management in adults with obesity or overweight who have weight-related medical conditions. It is a once-weekly injectable drug that works as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By targeting both pathways, Zepbound helps regulate appetite, improve blood sugar control, and promote significant weight loss when combined with healthy lifestyle changes such as diet and exercise.
Mounjaro (tirzepatide) is an FDA-approved injectable medication used to improve blood sugar control in adults with type 2 diabetes. It is the first dual-acting treatment that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, enhancing the body’s ability to regulate blood sugar and insulin levels. In addition to its effectiveness in managing diabetes, Mounjaro has also been shown to support meaningful weight loss when combined with healthy lifestyle changes.
RETATRUTIDE
(GLP-1/GIP/Glucagon)
Retatrutide is an investigational injectable medication currently being studied for weight management and metabolic health. It is a novel “triple agonist,” meaning it activates three key hormone receptors—GLP-1, GIP, and glucagon—that work together to regulate appetite, improve blood sugar control, and enhance energy metabolism. Early clinical trials have shown promising results, with participants experiencing significant weight loss and metabolic improvements, making retatrutide a potential next-generation therapy for obesity and related conditions.
Research has shown that obese adults lost up to 24.2% of their body weight in just 48 weeks, compared to 13.9% with Ozempic over 68 weeks and 17.8% with tirzepatide over 72 weeks. It is not FDA-approved but is currently in its 3rd phase of investigation with promising outcomes.
SERMORELIN (GHRH)
Sermorelin, a growth hormone–releasing hormone (GHRH) analog, is sometimes used off-label to support weight loss and body composition improvement. By stimulating the pituitary gland to naturally increase growth hormone production, sermorelin may help boost metabolism, promote fat breakdown, preserve lean muscle mass, and improve energy levels. When combined with a healthy diet and regular exercise, it can enhance overall wellness and support long-term weight management.